XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.4
Business Segment (Tables)
 9 Months Ended
Sep. 30, 2023
Business Segment [Abstract]  
Schedule of operations by business segment Summarized below is information about the Company’s operations for the three and nine months ended September 30, 2023 and 2022 by business segment:
   Three Months Ended September 30,   Nine Months Ended September 30, 
   Revenue   Earnings   Revenue   Earnings 
   2023   2022   2023   2022   2023   2022   2023   2022 
FOXO Labs  $6   $7   $(269)  $(500)  $20   $71   $(873)  $(1,952)
FOXO Life   4    7    (139)   (1,158)   15    22    (1,029)   (3,070)
    10    14    (408)   (1,658)   35    93    (1,902)   (5,022)
Impairment (a)             
-
    
-
              (2,633)   
-
 
Stock issuances (b)             
-
    
-
              (3,521)   
-
 
Corporate and other (c)             (3,104)   (38,944)             (13,671)   (70,660)
Interest expense             (148)   (424)             (865)   (1,250)
Total  $10   $14   $(3,660)  $(41,026)  $35   $93   $(22,592)  $(76,932)
(a) See Note 4 for additional information on the digital insurance platform, underwriting API, and longevity API impairment.
(b) Stock issuances includes the 2022 Bridge Debenture Release and the PIK Note Amendment. See Notes 5 and 7 for additional information.
(c) Corporate and other includes equity-based compensation, including the consulting agreement and Cantor Commitment Fee, expense of ($1,312) and $3,866 as well as depreciation and amortization expense of $5 and $74 for the three months ended September 30, 2023 and 2022, respectively. Corporate and other includes equity-based compensation, including the consulting agreement and Cantor Commitment Fee, expense of $2,582 and $5,556 as well as depreciation and amortization expense of $1,251 and $159 for the nine months ended September 30, 2023 and 2022, respectively. The three months ended September 30, 2023 and 2022 included ($36) and $31,010 for the changes in fair value of convertible debentures, warrant liability, and forward purchase derivatives. The nine months ended September 30, 2023 and 2022 also included ($244) and $55,493 for the changes in fair value of convertible debentures, warrant liability, and forward purchase derivatives. See Notes 4, 6, and 9 for additional information.